1. Introduction {#s0005}
===============

Posterior Reversible Encephalopathy Syndrome (PRES) is a clinical condition likely sustained by an impaired neurovascular unit autoregulation of the cerebral blood flow which, in turn, leads to endothelial dysfunction and vasogenic brain oedema. It recognizes different etiologies. Clinical presentation varies widely for both features and severity across reported case series and, at times, does not match either with the pattern or the amount of brain oedema on MRI [@bb0005]. Bartynski WS et al. [@bb0010] reported three major patterns consistent for typical PRES imaging: holohemispheric watershed (linear vasogenic oedema at anastomotic border zone spanning the frontal, parietal and occipital lobes with lesser temporal lobes involvement), superior frontal sulcal (involvement of the frontal lobe along the mid to posterior aspect of the superior frontal sulcus with no frontal pole extension) and dominant parietal-occipital (vasogenic oedema of the parietal and occipital cortex and white matter, variably extended to the temporal lobes). Partial or asymmetric expressions of the primary patterns (with, respectively, bilateral or unilateral absence of signal hyperintensity in either the parietal or occipital lobes) are possible. Brainstem involvement is infrequent and usually associated with the typical subcortical parietal-occipital bilateral sites of T2 hyperintensity [@bb0015].

2. Case description {#s0010}
===================

A 28 years-old woman, affected by Turner syndrome, epilepsy treated with oxcarbazepine 600 mg/day, slight mental deficiency, obesity and hypothyroidism in therapy with levothyroxine 125 μgr/day, was admitted with a progressive gait and standing impairment, worsening in the last 2 weeks. She had experienced episodes of tachycardia and acute hypertensive crisis in the past years, although blood pressure monitoring and 24-hour electrocardiogram were normal at that time. She was in ovarian hormone replacement treatment (gestodene 0.075 mg + ethinyl estradiol 0.03 mg/day). At admission blood pressure was 220/110 mmHg with heart rate of 120 bpm. Neurological examination showed inability at standing and walking, paraparesis, brisk reflexes at four limbs, and bilateral Babinski sign. Sensitivities were intact. The patient was confused but alert. Furosemide 25 mg was rapidly administered by infusion and transdermal patch clonidine 2.5 mg/week was prescribed. She underwent full blood examination (complete blood count, electrolytes, liver and kidney function, homocisteine, folate, B12 vitamin, vanilmandelic acid and chromogranine A levels, serum and urinary catecholamines and metanephrines, antiviral, bacterial, thrombophilic and autoimmune screenings), CSF examination, abdominal, renal arteries and cardiac ultrasound examinations (searching for causes of secondary arterial hypertension), thoracic aorta MRI (searching for aortic bicuspid valve or aortic arch abnormalities, typical in Turner syndrome, or possible dissecation). All these examinations were normal. Oxcarbazepine dosage and thyroid hormones were in range. 24-hour electrocardiogram showed sinusal tachycardia. A brain MRI at admission showed a wide FLAIR hyperintensity on T2-weighted sequences affecting the entire pons, without contrast enhancement ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Isolated involvement of the entire pons in FLAIR sequences at entry MRI.Fig. 1

Ovarian hormone replacement treatment was suspended. Clonidine transdermic patch 2.5 mg/week, doxazosine (tapering slowly up to 6 mg/day), furosemide (up to 50 mg/day) and telmisartan (80 mg/day) were effective in restoring normal blood pressure within 10 days together with concomitant return to normal neurological examination. Notably, at present, neither specific antihypertensive drug has been formally studied for the treatment nor randomized clinical trials assessing therapeutic interventions in PRES have been undertaken [@bb0005]. The selection of drugs is left to the discretion of the physician and our initial therapeutic goal was to reduce blood pressure by 25% within the first few hours, as recommended [@bb0020]. Beta-blockers for sinus tachycardia were initially delayed whereas possible neoplasm of chromaffin tissue was investigated. Repeated serum and urinary dosages of catecholamines, metanephrines, and vanilmandelic acid were normal 2 weeks after admission. A metaiodobenzylguanidine scintigraphy was performed to exclude a paraganglioma-pheochromocytoma and resulted normal. Then atenolol 50 mg/day was introduced successfully.

Pons hyperintensity was completely resolved on MRI performed 3 weeks after admission ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Complete resolution of pontineT2-hyperintensity at control MRI, after antihypertensive treatment and neurological recovery.Fig. 2

3. Discussion {#s0015}
=============

PRES with isolated pons involvement has been rarely described [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050] and only small series in the form of isolated pontine T2 hyperintensity on MRI have been reported [@bb0035]. Severe arterial hypertension alone [@bb0025] or in association with acute renal failure [@bb0035], highly active antiretroviral therapy [@bb0030], [@bb0050] and oxaliplatinum chemotherapy [@bb0045] have been described as precipitating factors in clinical settings of chronic renal failure [@bb0035], [@bb0040], arterial hypertension [@bb0025], AIDS [@bb0030], [@bb0050] and cancer [@bb0045]. To date, a review of seven brainstem PRES by Gao et al. [@bb0035] listed only one case with isolated pons lesion and spared supratentorial involvement. In this case dizziness and weakness were reported as clinical features in the context of arterial hypertension and chronic renal failure. The remaining six brainstem PRES cases in Gao and coll. showed a relatively mild clinical presentation wherein, apart from a case with coma, dizziness and instability were most commonly described. To our knowledge, only seven cases of pontine PRES has been published so far, as reported in [Table 1](#t0005){ref-type="table"}.Table 1Clinical features of 7 cases with isolated pons involvement in PRES reported in literature.Table 1Case no.Author (year)Age (years)sexBP (mmHg)Precipitating causeClinical settingSymptoms/signsOutcome1Gamanagatti S et al. (2006)60M220/150SHTNoneUnconscious state, bilateral papilloedemaR2Tanioka R et al. (2007)44Mranging from 130/75 to 96/50HAART + helminth infection treated with metronidazolAIDSMild psychiatric symptomsR3Gao B et al. (2012), case no 730M190/100SHT, ARFCRFDizziness, weakness of right limbsR4Liang H et al. (2013)36F260/140SHT, ISNewly diagnosed PSG with IgA nephropathyNausea, vomiting, right-sided weakness, right hemiparesis, Babinski signR5Tang KH (2015)81M140/85Oxaliplatin therapyMCCAltered mental status, drowsinessR6Cartier L et al. (2016)25Mdescribed as normalHAARTAIDSDizziness, postural instability, nistagmusR7Present case28F220/110SHT, OHRTTSGait and standing impairment, paraparesis, brisk reflexes at four limbs, bilateral Babinski signR[^1]

Overall, they show a dissociation between the mild clinical features, mostly not referable to the brainstem, and the severity of the MRI images [@bb0055], [@bb0060], [@bb0065], [@bb0070]. This pattern of *clinico*-*radiological dissociation* may be considered a key feature of brainstem PRES, and represents a clue for diagnosis and differentiation from typical PRES, the latter being associated to encephalopathy, seizures, status epilepticus, headache, visual disturbances and focal findings [@bb0005], usually with typical MRI imaging pattern [@bb0010].

Four out of 7 pontine PRES reported in [Table 1](#t0005){ref-type="table"} showed severe hypertension as precipitating factor [@bb0025], [@bb0035], [@bb0040] in the clinical context of renal diseases in 2 cases [@bb0035], [@bb0040] and apparently isolated in 1 case [@bb0025]. Renal failure is a classic disorder associated with PRES but whether it is an independent or a concurrent risk factor along with hypertension or autoimmune disorders is still unknown [@bb0005]. On the other hand, Liang et al. postulates that chronic renal failure, a well known risk factor for atherosclerotic disease, could determine PRES by participating to endothelial dysfunction in cerebral small vessels together with the acute increasing of vasoreactivity, hypertension-mediated [@bb0040]. Notably, patients with chronic kidney disease might also develop PRES with only a mild elevation of blood pressure because of electrolyte imbalance and protein urinary loss [@bb0075].

Our patient showed severe hypertension at admission likely linked to her Turner syndrome, and possibly precipited by the ovarian hormone replacement treatment. High blood pressure is actually reported in 13--58% of adults with Turner syndrome [@bb0080] and is presumably multifactorial. Interestingly, Turner syndrome is characterized by functional dysregulation of sympathetic nervous system and oxidative stress, both bringing to endothelial dysfunction and reduced vessel distensibility [@bb0080], which would be relevant in determining PRES.

Two cases in [Table 1](#t0005){ref-type="table"} are associated to acquired immune-deficiency syndrome. It is well known that HIV-1 infection can lead to vascular diseases by three pathogenetic mechanisms: direct HIV-1 mediated damage of vascular endothelium and associated chronic inflammation due to HIV-1 replication, side effects/off target effects from antiretroviral pharmacotherapy, changes in traditional risk factors such as tobacco abuse and dyslipidemia [@bb0085]. HIV-1 has long been known to directly injure the vascular endothelium inducing high secretion of some cytokines and growth factors by monocytes, macrophages and lymphocytes. These growth factors and cytokines can lead to dysregulation of endothelial and vascular smooth muscle cell growth and imbalance of endogenous vasodilators and constrictors (in favor of constrictors) [@bb0090]. Moreover, highly active antiretroviral therapy (HAART) can increase endothelial oxidative stress through escalated generation of reactive oxygen/nitrogen species (ROS/RNS) and impact the functional integrity of blood-brain barrier microvascular endothelium [@bb0095]. In these 2 cases reported in [Table 1](#t0005){ref-type="table"} both direct pathogenetic mechanisms of HIV-1 and side effects of antiretroviral therapy could have determined PRES, increasing cerebrovascular permeability and causing vasogenic oedema. Furthermore, the concomitant helminth infection in Case no 2 might have favored the release of additional mediators with increase of vascular permeability.

In the case reported by Tang [@bb0045], PRES could be presumably due to the oxaliplatin upregulation of vascular endothelial growth factor (VEGF) mRNA expression and VEGF receptors in human colorectal cancer cells [@bb0100]. In fact, circulating VEGF can promote vascular permeability and the development of interstitial oedema in PRES [@bb0005]. Expression of VEGF is regulated by several mediators and environmental conditions, one of the most potent being hypoxia which, actually, promotes signalling cascades to upregulate VEGF-A expression with final vasodilation and angiogenesis [@bb0100]. Interestingly, increased concentrations of VEGF-A have been observed in pre-eclampsia and eclampsia, both associated with PRES [@bb0005]. Furthermore, excessive circulating cytokines, a condition that typically accounts for endothelial dysfunction in autoimmune disorders and sepsis, can induce VEGF. These latter have been both reported as clinical conditions in PRES [@bb0005].

The underlying mechanism of a selective pontine involvement with sparing supratentorial lesions in PRES is not fully understood. In some susceptible patients acute hypertension, or pronounced fluctuations of blood pressure (like in hypotension and sepsis), could influence a breakdown in the blood-brain barrier with subsequent vasogenic oedema. The vertebro-basilar system is considered more vulnerable to imbalanced perfusion pressure because of its defective sympathetic-mediated vasocostriction which may have a protective role [@bb0005]. In a retrospective observational study aimed to correlate MRI patterns to clinical manifestations in PRES [@bb0105], the term *central*-*variant PRES* was introduced for a pattern, typically associated with severe hypertension, of selective vasogenic brainstem and basal ganglia oedema with sparing subcortical parietal-occipital white matter. According to authors, brain oedema prevalent in the supratentorial white matter correlates to moderate hypertension values, whilst an infratentorial involvement would account for cases with a prolonged history of persistent severe hypertension [@bb0105]. In a more recent retrospective observational study [@bb0110], the same authors tried to determine which structures are involved in the central variant of PRES and to describe the causes associated with this imaging pattern. Out of 124 PRES cases only 5 central-variant were sought, brainstem being involved in all of them. The causes of PRES in these five patients were hypertension (N = 2), immunosuppressive medication (both cyclosporine, N = 2), and eclampsia (N = 1). The authors ended up hypothising that a possible underlying mechanism for *central variant PRES* could be an increased sensitivity to endothelial cell dysfunction within smaller, perforating vessel supplying the brainstem from a cause not yet known. From this perspective, since the selective pattern of pontine involvement on MRI for central-variant PRES is quite uncommon and possible causes are many, a careful differential diagnosis is required. Our patient, in particular, showed a relatively mild clinical presentation without major brainstem signs despite the extensive radiological pattern of lesion. Symptoms didn\'t show a sudden onset but had been progressing over two weeks and features of vasogenic oedema on neuroimaging at entry with a complete resolution with no lesion in DWI and no restricted diffusion in the ADC map at control excluded pontine ischemia. Regression of signal hyperintensity in T2-weighted sequences at control MRI ruled out possible space-occupying mass, such as glioma, as well. Lacking fever both on the days before and at the time of symptoms onset, no contrast enhancement on MRI and the absence of CSF and blood chemistry abnormalities allowed to reject the hypothesis of possible acute demyelinating encephalomyelitis. Medical history and laboratory data have also disproved the hypothesis of an infectious episode of the brainstem. Finally, the isolated pontine lesion on MRI could lead to the suspicion of central pontine myelinolysis, but, the absence of hyponatremia at entry (hypothetically facilitated by oxcarbazepine intake) and at follow-up and a more extensive radiological pattern of pons involvement rather than a central selective one, ruled out that assumption.

4. Conclusions {#s0020}
==============

Central-variant should be considered an atypical pattern of PRES presentation with clinical-radiological dissociation possibly being the clue feature. All the seven pontine PRES cases reviewed here showed this fashion and severe hypertension acts as the more frequent precipitating factor. Isolated pontine involvement in neuroimaging is rare and, provided a correct identification of the precipitating causes, a complete clinical and radiological recovery was observed in all cases. Pontine localization can be very tricky and an accurate differential diagnosis must be sort out amongst a heterogeneous list of possible causes: to this regard ADC map and DWI sequences of MRI scans at onset and after recovery play an important role in distinguishing the vasogenic oedema from other possible entities. Physiopathogenetic mechanisms underlying PRES are not completely understood as the disease is described in a wide number of clinical contexts: nevertheless a possible peculiar poor pattern of vertebro-basilar sympathetic innervation of the brainstem along with an impaired neurovascular unit mechanism of cerebral blood flow autoregulation at different etiologies could be hypothised.

[^1]: *PRES* Posterior Reversible Encephalopathy Syndrome, *M* male, *SHT* severe hypertension, *R* resolution, *HAART* highly active antiretroviral therapy, *AIDS* acquired immune deficiency syndrome, *ARF* acute renal failure, *CRF* chronic renal failure, *F* female, *IS* ischemic stroke, *PSG* proliferative sclerosing glomerulonephritis, *MCC* metastatic colorectal carcinoma, *OHRT* ovarian hormone replacement treatment, *TS* Turner syndrome.
